[
  {
    "ts": null,
    "headline": "BlackRock Tactical Opportunities Fund Q4 2024 Commentary",
    "summary": "BlackRock Tactical Opportunities Fund posted Q4 2024 returns of 4.65% (Institutional shares) and 4.58% (Investor A shares, without sales charge), while BofA ML 3-Month T-Bill returned 1.17%.",
    "url": "https://finnhub.io/api/news?id=48c57fbb2e8ef464f3bf00611efed384dca5d8c93e7edb9650bc211c8eb94fd2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742508780,
      "headline": "BlackRock Tactical Opportunities Fund Q4 2024 Commentary",
      "id": 133295029,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1511226415/image_1511226415.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "BlackRock Tactical Opportunities Fund posted Q4 2024 returns of 4.65% (Institutional shares) and 4.58% (Investor A shares, without sales charge), while BofA ML 3-Month T-Bill returned 1.17%.",
      "url": "https://finnhub.io/api/news?id=48c57fbb2e8ef464f3bf00611efed384dca5d8c93e7edb9650bc211c8eb94fd2"
    }
  },
  {
    "ts": null,
    "headline": "Tracking Philippe Laffont's Coatue Management Portfolio - Q4 2024 Update",
    "summary": "Coatue Management's 13F portfolio increased from $26.92B to $29.68B. Read here for latest updates like new stakes, top holdings, and major changes in tech giants.",
    "url": "https://finnhub.io/api/news?id=6d8832482796059cc517c0cf653abbd3075425615bd6e0e849beddef24fd9037",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742500905,
      "headline": "Tracking Philippe Laffont's Coatue Management Portfolio - Q4 2024 Update",
      "id": 133294635,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/472298390/image_472298390.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Coatue Management's 13F portfolio increased from $26.92B to $29.68B. Read here for latest updates like new stakes, top holdings, and major changes in tech giants.",
      "url": "https://finnhub.io/api/news?id=6d8832482796059cc517c0cf653abbd3075425615bd6e0e849beddef24fd9037"
    }
  },
  {
    "ts": null,
    "headline": "Factbox-Lilly's weight-loss drug launch in India to energize rivals eyeing mega market",
    "summary": "Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug: NOVO NORDISK The Danish drugmaker had said it aims to launch its blockbuster weight-loss drug, Wegovy, in India by 2026. The active ingredient in Wegovy is semaglutide, which is likely to go off-patent in 2026 in India. Wegovy and Lilly's Mounjaro belong to the same class of treatments called GLP-1 agonists, which soared into popularity globally triggering a shortage of supply.",
    "url": "https://finnhub.io/api/news?id=9466d589db9a274fda91392a450c2d55ed16bfc4095160942ccfe6d0fa8fa8d1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742486795,
      "headline": "Factbox-Lilly's weight-loss drug launch in India to energize rivals eyeing mega market",
      "id": 133324409,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug: NOVO NORDISK The Danish drugmaker had said it aims to launch its blockbuster weight-loss drug, Wegovy, in India by 2026. The active ingredient in Wegovy is semaglutide, which is likely to go off-patent in 2026 in India. Wegovy and Lilly's Mounjaro belong to the same class of treatments called GLP-1 agonists, which soared into popularity globally triggering a shortage of supply.",
      "url": "https://finnhub.io/api/news?id=9466d589db9a274fda91392a450c2d55ed16bfc4095160942ccfe6d0fa8fa8d1"
    }
  },
  {
    "ts": null,
    "headline": "3 Promising Biotechs Trading Substantially Under Consensus Analyst Firm Price Targets",
    "summary": "Discover three undervalued biotech stocks with strong assets, solid cash reserves, and major catalysts ahead. Click for the picks and why I like them.",
    "url": "https://finnhub.io/api/news?id=18230ff58e9aced29e03768ed7243a564c5bfe4a848f02601a418129b3decaba",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742475790,
      "headline": "3 Promising Biotechs Trading Substantially Under Consensus Analyst Firm Price Targets",
      "id": 133287278,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155151969/image_155151969.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover three undervalued biotech stocks with strong assets, solid cash reserves, and major catalysts ahead. Click for the picks and why I like them.",
      "url": "https://finnhub.io/api/news?id=18230ff58e9aced29e03768ed7243a564c5bfe4a848f02601a418129b3decaba"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to launch Mounjaro pen in India as Novo rivalry heats up in mega market",
    "summary": "India's drug regulator on Thursday approved the launch of pre-filled injector pens of Eli Lilly's blockbuster weight-loss drug, Mounjaro, giving the company more options to compete with rival Novo...",
    "url": "https://finnhub.io/api/news?id=7940ba48c816bad3e6b4ba9b6dc2ae6cae53d04dbb1c3362459883cf64331bf9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742472521,
      "headline": "Lilly to launch Mounjaro pen in India as Novo rivalry heats up in mega market",
      "id": 135559719,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "India's drug regulator on Thursday approved the launch of pre-filled injector pens of Eli Lilly's blockbuster weight-loss drug, Mounjaro, giving the company more options to compete with rival Novo...",
      "url": "https://finnhub.io/api/news?id=7940ba48c816bad3e6b4ba9b6dc2ae6cae53d04dbb1c3362459883cf64331bf9"
    }
  },
  {
    "ts": null,
    "headline": "BlackRock Large Cap Focus Growth Fund Q4 2024 Commentary",
    "summary": "The fund posted returns of 6.03%Â (Institutional shares) and 5.84%Â (Investor A shares, without sales charge) for the fourth quarter of 2024.",
    "url": "https://finnhub.io/api/news?id=861c74c37b169204812bd3cf18c7d51325816556763ccb30448b6c558bbf4150",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742465400,
      "headline": "BlackRock Large Cap Focus Growth Fund Q4 2024 Commentary",
      "id": 133276812,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1421629295/image_1421629295.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The fund posted returns of 6.03%Â (Institutional shares) and 5.84%Â (Investor A shares, without sales charge) for the fourth quarter of 2024.",
      "url": "https://finnhub.io/api/news?id=861c74c37b169204812bd3cf18c7d51325816556763ccb30448b6c558bbf4150"
    }
  },
  {
    "ts": null,
    "headline": "5 Reasons It's Not Too Late to Buy Eli Lilly Stock",
    "summary": "Eli Lilly (NYSE: LLY) has been around for almost 150 years, finding ways to innovate and grow.  The next largest healthcare company is UnitedHealth Group, which is worth less than $450 billion.  Over the past five years, Eli Lilly's stock has soared by around 530%, soundly beating the S&P 500 and its 136% gain during the same time frame.",
    "url": "https://finnhub.io/api/news?id=ba6ff630752816e6160f9da4c4ea97cf1631ba7fb874cc4711b11b366f9f23f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742462700,
      "headline": "5 Reasons It's Not Too Late to Buy Eli Lilly Stock",
      "id": 133324410,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE: LLY) has been around for almost 150 years, finding ways to innovate and grow.  The next largest healthcare company is UnitedHealth Group, which is worth less than $450 billion.  Over the past five years, Eli Lilly's stock has soared by around 530%, soundly beating the S&P 500 and its 136% gain during the same time frame.",
      "url": "https://finnhub.io/api/news?id=ba6ff630752816e6160f9da4c4ea97cf1631ba7fb874cc4711b11b366f9f23f2"
    }
  },
  {
    "ts": null,
    "headline": "Invesco American Franchise Fund Q4 2024 Commentary",
    "summary": "The fund outperformed its benchmark and peers for the final quarter and full year 2024, driven by positive stock selection.",
    "url": "https://finnhub.io/api/news?id=0cd13fc08d4ce6b9816bba245a2003d62ea169e7a9e1c8f3ac7b61ca90aa6b57",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742462400,
      "headline": "Invesco American Franchise Fund Q4 2024 Commentary",
      "id": 133274172,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1453695647/image_1453695647.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The fund outperformed its benchmark and peers for the final quarter and full year 2024, driven by positive stock selection.",
      "url": "https://finnhub.io/api/news?id=0cd13fc08d4ce6b9816bba245a2003d62ea169e7a9e1c8f3ac7b61ca90aa6b57"
    }
  },
  {
    "ts": null,
    "headline": "Invesco Health Care Fund Q4 2024 Commentary",
    "summary": "Stock selection in life science tools & services, pharmaceuticals and distributors detracted from relative performance, as did an overweight in health care facilities.",
    "url": "https://finnhub.io/api/news?id=8f81827abb6ec00be306ef52a83e31acbe2c243bf3d6f7d992305822a81d2a8e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742461500,
      "headline": "Invesco Health Care Fund Q4 2024 Commentary",
      "id": 133273550,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154850841/image_2154850841.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Stock selection in life science tools & services, pharmaceuticals and distributors detracted from relative performance, as did an overweight in health care facilities.",
      "url": "https://finnhub.io/api/news?id=8f81827abb6ec00be306ef52a83e31acbe2c243bf3d6f7d992305822a81d2a8e"
    }
  },
  {
    "ts": null,
    "headline": "SPXE: Overtaking SPY Without Fuel",
    "summary": "The ProShares S&P 500Â® ex-Energy ETF invests in S&P 500 companies, excluding those in the GICS energy sector. Read why SPXE ETF is a Hold.",
    "url": "https://finnhub.io/api/news?id=bd3e9d2fe8904bbfbb059249bb619468af1b6d3e0b572c4fb6fba7e9d3b536cb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742461200,
      "headline": "SPXE: Overtaking SPY Without Fuel",
      "id": 133273033,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/200437178/image_200437178.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The ProShares S&P 500Â® ex-Energy ETF invests in S&P 500 companies, excluding those in the GICS energy sector. Read why SPXE ETF is a Hold.",
      "url": "https://finnhub.io/api/news?id=bd3e9d2fe8904bbfbb059249bb619468af1b6d3e0b572c4fb6fba7e9d3b536cb"
    }
  },
  {
    "ts": null,
    "headline": "EU health regulator clears use of AI tool in fatty liver disease trials",
    "summary": "A European Medicines Agencycommittee, on Thursday, accepted the use of an artificialintelligence tool called AIM-NASH in clinical trials tohelp identify the severity of a type of fatty liver...",
    "url": "https://finnhub.io/api/news?id=53c956151932f02bb57a449622f571a5377cc5e70617de010f927a7a63b5ed6a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742458482,
      "headline": "EU health regulator clears use of AI tool in fatty liver disease trials",
      "id": 133269681,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "A European Medicines Agencycommittee, on Thursday, accepted the use of an artificialintelligence tool called AIM-NASH in clinical trials tohelp identify the severity of a type of fatty liver...",
      "url": "https://finnhub.io/api/news?id=53c956151932f02bb57a449622f571a5377cc5e70617de010f927a7a63b5ed6a"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly launches weight-loss drug Mounjaro in India, beats Novo Nordisk to major market",
    "summary": "HYDERABAD (Reuters) -Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk for a much-awaited entry into the world's most populous country grappling with increasing rates of obesity and diabetes.  U.S.-based Lilly and Danish Novo Nordisk have seen skyrocketing global demand for their innovative weight-loss drugs, with investor interest also boosting the drugmakers' valuations.  Mounjaro, a once-weekly injection approved by India's drug regulator, is priced at 4,375 rupees ($50.67) for a 5 mg vial and 3,500 rupees ($40.54) for a 2.5 mg vial, its lowest doses, the company told Reuters exclusively.",
    "url": "https://finnhub.io/api/news?id=506d969a677438853cbaa67cc1522df4d11d36247f69e5ce0e19b72df49c8626",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742453657,
      "headline": "Eli Lilly launches weight-loss drug Mounjaro in India, beats Novo Nordisk to major market",
      "id": 133324411,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "HYDERABAD (Reuters) -Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk for a much-awaited entry into the world's most populous country grappling with increasing rates of obesity and diabetes.  U.S.-based Lilly and Danish Novo Nordisk have seen skyrocketing global demand for their innovative weight-loss drugs, with investor interest also boosting the drugmakers' valuations.  Mounjaro, a once-weekly injection approved by India's drug regulator, is priced at 4,375 rupees ($50.67) for a 5 mg vial and 3,500 rupees ($40.54) for a 2.5 mg vial, its lowest doses, the company told Reuters exclusively.",
      "url": "https://finnhub.io/api/news?id=506d969a677438853cbaa67cc1522df4d11d36247f69e5ce0e19b72df49c8626"
    }
  },
  {
    "ts": null,
    "headline": "Lilly Says Mounjaro 2.5 Mg Vial Priced At 3,500 Rupees In India",
    "summary": "Eli Lilly and Co: * LILLY SAYS MOUNJARO 2.5 MG VIAL PRICED AT 3,500 RUPEES ININDIA * LILLY SAYS MOUNJARO 5 MG VIAL PRICED AT 4,375 RUPEES ININDIASource text:Further...",
    "url": "https://finnhub.io/api/news?id=6c88c6bfe2c5654a7318896743a7817f0ecee6b389cffec8d6545c7d228fa810",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742445331,
      "headline": "Lilly Says Mounjaro 2.5 Mg Vial Priced At 3,500 Rupees In India",
      "id": 133268250,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly and Co: * LILLY SAYS MOUNJARO 2.5 MG VIAL PRICED AT 3,500 RUPEES ININDIA * LILLY SAYS MOUNJARO 5 MG VIAL PRICED AT 4,375 RUPEES ININDIASource text:Further...",
      "url": "https://finnhub.io/api/news?id=6c88c6bfe2c5654a7318896743a7817f0ecee6b389cffec8d6545c7d228fa810"
    }
  },
  {
    "ts": null,
    "headline": "Lilly India Launches Mounjaro, Offering New Option For Treatment Of Obesity And Type 2 Diabetes",
    "summary": "Eli Lilly and Co: * LILLY LAUNCHES MOUNJARO, OFFERING A NEW OPTION FOR THETREATMENTOF OBESITY AND TYPE 2 DIABETE- STATEMENT * LILLY INDIA: LAUNCHES MOUNJARO, NEW OPTION...",
    "url": "https://finnhub.io/api/news?id=518059c56da9a4a445bd0d6aab25c3897a935a2c6671421a28ce9a408ebb98ae",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742440786,
      "headline": "Lilly India Launches Mounjaro, Offering New Option For Treatment Of Obesity And Type 2 Diabetes",
      "id": 133267686,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly and Co: * LILLY LAUNCHES MOUNJARO, OFFERING A NEW OPTION FOR THETREATMENTOF OBESITY AND TYPE 2 DIABETE- STATEMENT * LILLY INDIA: LAUNCHES MOUNJARO, NEW OPTION...",
      "url": "https://finnhub.io/api/news?id=518059c56da9a4a445bd0d6aab25c3897a935a2c6671421a28ce9a408ebb98ae"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly launches weight-loss drug Mounjaro in India after drug regulator approval",
    "summary": "Eli Lilly has launched itsblockbuster diabetes and weight-loss drug Mounjaro in Indiafollowing approval from the country's drug regulator, it said onThursday. Global demand for...",
    "url": "https://finnhub.io/api/news?id=93cd227c009af19bd33f476beb5bf4a00ef000bb4fc274e8cd843fecd66f8982",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742439985,
      "headline": "Eli Lilly launches weight-loss drug Mounjaro in India after drug regulator approval",
      "id": 133267614,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly has launched itsblockbuster diabetes and weight-loss drug Mounjaro in Indiafollowing approval from the country's drug regulator, it said onThursday. Global demand for...",
      "url": "https://finnhub.io/api/news?id=93cd227c009af19bd33f476beb5bf4a00ef000bb4fc274e8cd843fecd66f8982"
    }
  }
]